固形がん患者を対象としたE7386と他の抗がん剤の併用試験

基本情報

NCT ID: NCT04008797
ステータス: 募集中
試験のフェーズ: 第1/第2相
試験タイプ: 介入
目標被験者数: 301
治験依頼者名: Eisai Inc.

概要

The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s), and to determine the optimal dose of E7386 in combination with lenvatinib in endometrial carcinoma (EC) (for EC Dose Optimization Part only).

対象疾患

Endometrial NeoplasmsNeoplasmsCarcinoma, HepatocellularLiver NeoplasmsColorectal Neoplasms

介入

E7386(DRUG)

Lenvatinib(DRUG)

Doxorubicin(DRUG)

Paclitaxel(DRUG)

依頼者（Sponsor）

エーザイ株式会社(INDUSTRY)

実施施設 (15)

Eisai#1011

Toyoake, Aichi-ken, Japan(RECRUITING)

Eisai#1008

Matsuyama, Ehime, Japan(COMPLETED)

Eisai#1007

Kurume, Fukuoka, Japan(RECRUITING)

Eisai#1009

Hidaka, Saitama, Japan(RECRUITING)

Eisai#1004

Chiba, Japan(COMPLETED)

Eisai#1006

Koto-ku, Tokyo, Japan(RECRUITING)

Eisai#1005

Nagoya, Aichi-ken, Japan(RECRUITING)

Eisai#1002

Kashiwa, Chiba, Japan(RECRUITING)

Eisai#1012

Kamigyō-ku, Kyoto, Japan(COMPLETED)

Eisai#1014

Niigata, Japan(RECRUITING)

Eisai#1010

Kawasaki, Kanagawa, Japan(ACTIVE_NOT_RECRUITING)

Eisai#1001

Chuo-ku, Tokyo, Japan(RECRUITING)

Eisai#1015

Minato-ku, Tokyo, Japan(RECRUITING)

Eisai#1003

Sayama, Osaka, Japan(COMPLETED)

Eisai#1013

Akashi, Hyōgo, Japan(RECRUITING)